SALL2 activity could be restored using DNA methyltransferase (DNMT), therefore co-administration of tamoxifen and DNMT inhibitors like 5-Aza-20-deoxycytidine (5-Aza-dC), is a rational approach to re-sensitize patients tamoxifen resistant breast cancer patients [58]. This evidence concerns the gene DNMT1 and breast carcinoma.